Harvest Fund Management Co. Ltd Has $123,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Harvest Fund Management Co. Ltd reduced its stake in shares of Stryker Co. (NYSE:SYK) by 13.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 340 shares of the medical technology company’s stock after selling 54 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Stryker were worth $123,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of SYK. Centennial Bank AR lifted its position in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 48 shares in the last quarter. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at about $36,000. HBW Advisory Services LLC bought a new stake in shares of Stryker in the third quarter valued at about $42,000. Hara Capital LLC bought a new stake in shares of Stryker in the third quarter valued at about $42,000. Finally, Grove Bank & Trust boosted its position in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after buying an additional 56 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total value of $784,770.00. Following the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,781 shares of company stock worth $24,612,275. Company insiders own 5.50% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $388.14 on Thursday. Stryker Co. has a fifty-two week low of $285.79 and a fifty-two week high of $398.20. The company’s 50-day moving average is $367.50 and its 200-day moving average is $350.68. The firm has a market capitalization of $147.97 billion, a PE ratio of 41.60, a PEG ratio of 2.90 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.46 earnings per share. Equities analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on SYK shares. Piper Sandler reissued an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Royal Bank of Canada lifted their price objective on shares of Stryker from $386.00 to $400.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. increased their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a report on Wednesday, October 30th. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, UBS Group boosted their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.